HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Popovic, B. Articles by Sivaswamy, L. PubMed PubMed Citation Articles by Popovic, B. Articles by Sivaswamy, L.

BILJANA POPOVIC, PHARM.D., BCPS, BCNSP, is Pharmacist, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY. PRATIK BHATTACHARYA, M.D., M.P.H., is Neurology Resident, Wayne State University (WSU), Detroit. LALITHA SIVASWAMY, M.D., is Director of Pediatric Neurology Residency Program, Department of Neurology, WSU, and Assistant Professor of Neurology and Pediatrics, Carman and Ann Adams Department of Pediatrics, Children’s Hospital of Michigan, Detroit.

Address correspondence to Dr. Popovic at New York-Presbyterian Hospital, Main Pharmacy, Vanderbilt Clinic Building, 622 West 168th Street, New York, NY 10032 (bip9009{at}nyp.org).

Purpose. The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, dosage, and administration of lisdexamfetamine are reviewed. Summary. Lisdexamfetamine is the first prodrug formulation of the stimulant dextroamphetamine. It is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children age 6–12 years and adults. Due to the need for enzymatic hydrolysis, there is a decreased liability for misuse and diversion with lisdexamfetamine. Moreover, due to the rate-limiting nature of hydrolysis, the toxicity potential and chances of overdose with lisdexamfetamine are reduced. The recommended starting dosage of lisdexamfetamine is 30 mg orally daily, which can be adjusted to a maximum dosage of 70 mg daily. Clinical trials in children age 6–12 years with ADHD found significant reductions in the ADHD symptoms with lisdexamfetamine compared with placebo. However, clinical studies in adolescents have not been conducted. The efficacy and safety of lisdexamfetamine in children with ADHD and comorbid psychiatric disorders also remain to be assessed. A controlled trial in adults similarly showed significant improvements in ADHD symptoms in all treatment groups. Long-term clinical trials and head-to-head comparison trials with existing stimulant formulations are necessary. The most common adverse effects include decreased appetite, insomnia, irritability, dizziness, and weight loss. Conclusion. Clinical trials in children age 6–12 years and adults with ADHD have shown lisdexamfetamine to be safe and effective, with significant improvement of ADHD-related rating scores. However, the efficacy and safety of lisdexamfetamine in children with ADHD and comorbid psychiatric disorders have not been assessed. Index terms: Attention deficit disorder with hyperactivity; Central nervous system stimulants; Dosage; Drug administration; Drug interactions; Drugs; Hydrolysis; Lisdexamfetamine; Pediatrics; Pharmacokinetics; Toxicity

 

This article has been cited by other articles:

				A. Jun Attention-deficit/hyperactivity disorder: The road traveled and the road ahead Am. J. Health Syst. Pharm., November 15, 2009; 66(22): 2003 - 2003. [Full Text] [PDF]